163 related articles for article (PubMed ID: 10936336)
1. Administration of CTLA4-Ig enhances the incidence of hamster-to-rat xenogeneic bone marrow engraftment and alters the presentation of graft-vs-host disease.
Lee YH; Miki T; Kuddus R; Tandin A; Goller AL; Subbotin V; Fung JJ; Peach R; Valdivia LA; Rao AS
Transplant Proc; 2000 Aug; 32(5):1032-3. PubMed ID: 10936336
[No Abstract] [Full Text] [Related]
2. Role of peripheral clonal deletion in tolerance induction with bone marrow transplantation and costimulatory blockade.
Wekerle T; Sayegh MH; Chandraker A; Swenson KG; Zhao Y; Sykes M
Transplant Proc; 1999; 31(1-2):680. PubMed ID: 10083292
[No Abstract] [Full Text] [Related]
3. Xenogeneic humoral graft-Vs-host disease following hamster-to-Rat bone marrow transplantation.
Miki T; Lee YH; Tandin A; Subbotin V; Kuddus R; Rao AS; Fung JJ; Starzl TE; Valdivia LA
Transplant Proc; 2000 Aug; 32(5):1036-7. PubMed ID: 10936339
[No Abstract] [Full Text] [Related]
4. Stable mixed hematopoietic chimerism in dogs given donor antigen, CTLA4Ig, and 100 cGy total body irradiation before and pharmacologic immunosuppression after marrow transplant.
Storb R; Yu C; Zaucha JM; Deeg HJ; Georges G; Kiem HP; Nash RA; McSweeney PA; Wagner JL
Blood; 1999 Oct; 94(7):2523-9. PubMed ID: 10498626
[TBL] [Abstract][Full Text] [Related]
5. Tolerating differences.
Sikorski R; Peters R
Science; 1999 Jul; 285(5426):357-8. PubMed ID: 10438301
[No Abstract] [Full Text] [Related]
6. Effect of tacrolimus and splenectomy on engraftment and GVHD after bone marrow xenotransplantation in the reciprocal hamster to rat animal models.
Pan F; Tsugita M; Rao AS; Wakizaka Y; Sun H; Park IY; Fung JJ; Starzl TE; Valdivia LA
Transplant Proc; 1996 Apr; 28(2):736-7. PubMed ID: 8623373
[No Abstract] [Full Text] [Related]
7. Immunomodulation with intrathymic injection of donor splenocytes followed by CTLA4Ig therapy prolongs small intestinal allograft survival.
Greenstein SM; Sun S; Schechner RS; Tellis VA
Transplant Proc; 1997; 29(1-2):1065-6. PubMed ID: 9123201
[No Abstract] [Full Text] [Related]
8. Prolonged allograft survival but no tolerance induction by modulating CD28 antibody JJ319 after high-responder rat heart transplantation.
Dengler TJ; Szabo G; Sido B; Nottmeyer W; Zimmerman R; Vahl CF; Hünig T; Meuer SC
Transplantation; 1999 Feb; 67(3):392-8. PubMed ID: 10030284
[TBL] [Abstract][Full Text] [Related]
9. Use of CTLA4-Ig in combination with conventional immunosuppressive agents to prolong allograft survival.
Hale DA; Gottschalk R; Maki T; Monaco AP
Transplantation; 1997 Sep; 64(6):897-900. PubMed ID: 9326417
[TBL] [Abstract][Full Text] [Related]
10. Transplantation of anergic histoincompatible bone marrow cells.
de Carvalho Bittencourt M; Tiberghien P; Saas P
N Engl J Med; 1999 Sep; 341(14):1081-2. PubMed ID: 10507928
[No Abstract] [Full Text] [Related]
11. CTLA4Ig treatment ameliorates the lethality of murine graft-versus-host disease across major histocompatibility complex barriers.
Wallace PM; Johnson JS; MacMaster JF; Kennedy KA; Gladstone P; Linsley PS
Transplantation; 1994 Sep; 58(5):602-10. PubMed ID: 8091487
[TBL] [Abstract][Full Text] [Related]
12. Hamster-to-rat bone marrow xenotransplantation and humoral graft vs. host disease.
Miki T; Lee YH; Tandin A; Subbotin V; Goller A; Kovscek A; Fung JJ; Valdivia LA
Xenotransplantation; 2001 Aug; 8(3):213-21. PubMed ID: 11472629
[TBL] [Abstract][Full Text] [Related]
13. CTLA4-Ig treatment prolongs rat orthotopic liver graft survival.
Tu Y; Rehman A; Flye MW
Transplant Proc; 1997; 29(1-2):1036-7. PubMed ID: 9123186
[No Abstract] [Full Text] [Related]
14. CTLA4-Ig plus bone marrow induces long-term allograft survival and donor specific unresponsiveness in the murine model. Evidence for hematopoietic chimerism.
Pearson TC; Alexander DZ; Hendrix R; Elwood ET; Linsley PS; Winn KJ; Larsen CP
Transplantation; 1996 Apr; 61(7):997-1004. PubMed ID: 8623206
[TBL] [Abstract][Full Text] [Related]
15. Combined host-conditioning with CTLA4-Ig, tacrolimus, anti-lymphocyte serum, and low-dose radiation leads to stable mixed hematopoietic chimerism.
Li S; Thanikachalam M; Pang M; Carreno M; Aitouche A; Pham SM
Exp Hematol; 2001 Apr; 29(4):534-41. PubMed ID: 11301194
[TBL] [Abstract][Full Text] [Related]
16. Prolongation of rat to mouse skin and heart xenograft survival by combined CTLA4Ig and anti-CD4/CD8 antibody.
Tu Y; Rehman A; Flye MW
Transplant Proc; 1996 Aug; 28(4):2061-2. PubMed ID: 8769156
[No Abstract] [Full Text] [Related]
17. Combined CTLA4Ig and anti-CD4/DC8 monoclonal antibody treatment prolongs survival of rat-to-mouse heterotopic cardiac xenografts.
Rehman A; Tu Y; Flye MW
Transplant Proc; 1996 Apr; 28(2):660-1. PubMed ID: 8623331
[No Abstract] [Full Text] [Related]
18. In vivo blockade of CD28/CTLA4: B7/BB1 interaction with CTLA4-Ig reduces lethal murine graft-versus-host disease across the major histocompatibility complex barrier in mice.
Blazar BR; Taylor PA; Linsley PS; Vallera DA
Blood; 1994 Jun; 83(12):3815-25. PubMed ID: 7515723
[TBL] [Abstract][Full Text] [Related]
19. Prolongation of rat small bowel allograft survival by CTLA-4 IG.
Tarumi K; Yagihashi A; Murakami M; Uede T; Hirata K
Transplant Proc; 1998 Sep; 30(6):2596-9. PubMed ID: 9745507
[No Abstract] [Full Text] [Related]
20. New developments in the prophylaxis and treatment of graft versus host disease.
Simpson D
Expert Opin Pharmacother; 2001 Jul; 2(7):1109-17. PubMed ID: 11583062
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
